Shaoyan Xi

6PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical devicesEpigenetics (incl. genome methylation and epigenomics)Neural engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 26, 2025
MYCN amplification defines an aggressive phenotype in IDH-mutant gliomas.

Xujun Xie, Qin Yan, Fang Wang

|Jun 26, 2025
CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma.

Feifei Luo, Yan Mei, Yanwen Li

|Jun 05, 2025
A Novel Germline MUTYH Mutation (p.W156∗) in High-Grade Astrocytoma, IDH Mutant.

|Feb 27, 2024
Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.

Shaoyan Xi, Shimeng Jiang, Hainan Li

|Jan 04, 2024
A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.

Shaoyan Xi, Qitao Huang, Jing Zeng

|Jul 20, 2022
Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma.

Xiangrong Ni, Weichi Wu, Xiaoqiang Sun

Pageof 1

Frequent Collaborators

1 joint publications

Xiangrong Ni

1 joint publications

Weichi Wu

1 joint publications

Xiaoqiang Sun

1 joint publications

Junxiao Ma